| Ex Vivo and In Vivo CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26) JR Hemsath, AM Liaci, JD Rubin, BJ Parrett, SC Lu, TV Nguyen, ... Journal of virology 96 (3), e00826-21, 2022 | 17 | 2022 |
| Modulating oncolytic adenovirus immunotherapy by driving two axes of the immune system by expressing 4-1bbl and cd40l SC Lu, MJ Hansen, JR Hemsath, BJ Parrett, BN Zell, MA Barry Human gene therapy 33 (5-6), 250-261, 2022 | 11 | 2022 |
| Host-viral interactions at the maternal-fetal interface. What we know and what we need to know JH Girsch, MC Mejia Plazas, A Olivier, M Farah, D Littlefield, S Behl, ... Frontiers in Virology 2, 833106, 2022 | 10 | 2022 |
| Comparison of replicating and nonreplicating vaccines against SARS-CoV-2 HE Mudrick, S Massey, EB McGlinch, BJ Parrett, JR Hemsath, ME Barry, ... Science Advances 8 (34), eabm8563, 2022 | 8 | 2022 |
| Comparison of mucosal and intramuscular immunization against SARS-CoV-2 with replication-defective and replicating single-cycle adenovirus vaccines HE Mudrick, EB McGlinch, BJ Parrett, JR Hemsath, ME Barry, JD Rubin, ... bioRxiv, 2021.04. 20.440651, 2021 | 2 | 2021 |
| Ex VivoandIn VivoCD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26) JR Hemsath, AM Liaci, JD Rubin, BJ Parrett, S Lu, TV Nguyen, MA Turner, ... | | 2021 |
| Activity of Phosvitin in Hydroxyapatite Acid‐Damage Immersion and Antimicrobial Assays RD Shipman, SD Doering, JR Hemsath, EJ Lee, JE Grant Biochemistry research international 2020 (1), 8831311, 2020 | | 2020 |
